To support the development of novel antimicrobials, Pharmacology Discovery Services provides both in vitro and in vivo antimicrobial drug discovery services. Our in vitro microbiology services includes Minimum Inhibitory Concentration (MIC) testing with over 850 strains. Most strains are phenotyped, and the acquired antibiotic-resistance genes are genotyped. Over 145 validated in vivo efficacy models are also available with a variety of infection types: dermal, lung, thigh, peritonitis, septicemia, urinary tract infection (UTI), and vaginal. We also provide in vivo Pharmacokinetic (PK) studies to enable the evaluation of compounds prior to conducting efficacy studies. All study protocols are written and reviewed by our team of highly experienced antimicrobial Technical and Study Directors. Our team can also develop custom services to meet the specific needs of your drug discovery program.

Through our Partner Lab, Eurofins Discovery, our clients also have access to other services, including in vitro pharmacology, in vitro ADME-Tox, and assay development services. With the breadth of antimicrobial drug discovery services from Pharmacology Discovery Services and other assays provided by Eurofins Discovery, our clients have access to thousands of assays to support their drug discovery programs.